ALGM vs FROG

ALGM's deterministic health scores signal significant financial distress: the Piotroski F-Score of 2/9 indicates weak operational and financial health, while the absence of an Altman Z-Score raises concerns about bankruptcy risk. Despite strong revenue growth (28.9% YoY) and positive earnings momentum (114.3% YoY EPS growth), the company reports negative profit margins (-1.57%) and ROE (-1.36%), undermining profitability sustainability. Insider selling totaling $1.65M over six months and a bearish technical trend further erode confidence. The stock trades at a premium valuation (Forward P/E: 33.05, Price/Sales: 6.87) relative to its weak fundamentals, suggesting overvaluation.

FROG presents a dichotomy between strong growth fundamentals and concerning internal sentiment. The company maintains a stable financial health profile with a Piotroski F-Score of 5/9 and a pristine balance sheet (Debt/Equity of 0.01), though it remains GAAP unprofitable with a -13.50% profit margin. While revenue growth is robust at 25.20% and earnings consistently beat estimates, the bearish insider signal (CEO/CFO selling) and a 0/100 technical trend offset the 'Strong Buy' analyst consensus. The stock is currently valued as a high-growth asset, trading at a premium P/S ratio of 10.13.